Arbutus biopharma company has released the preliminary results of ab-506 single drug treatment phase IA / IB clinical research

Recently, arbutus biopharma (http:// published the preliminary results of single drug treatment of phase IA / IB clinical research health (http:// and two cohorts of chronic hepatitis B (CHB) subjects These results support the potential of ab-506 as part of the combination therapy to inhibit HBV replication Ab-506 ab-506 is an oral class II HBV capsid inhibitor HBV core protein is assembled into capsid structure, which is necessary for virus replication At present, the standard nursing therapy of HBV is mainly nucleoside analogues, which can significantly reduce virus replication by preventing virus polymerase, but not completely inhibit it Capsid inhibitors inhibit replication by blocking the assembly of functional viral capsids and inhibiting the de coating step of virus life cycle, thereby reducing the formation of new covalently closed circular DNA (cccDNA), a virus repository located in the nucleus A detailed analysis of the preliminary results of the IA / IB phase study (http:// including a complete description of the ALT flare cases and preliminary results of the new 28 day study on healthy subjects, will be presented at a scientific conference later this year (http://